This page shows prior authorization criteria extracted from Anthem BCBS (Carelon)'s published imaging guidelines. 80 matching coverage rules found for this procedure.
Abdominal and/or pelvic pain, undifferentiated
Indication Code: CARELON-ABDPEL-058
Acute Leukemia
Indication Code: CARELON-ONC-027
Adrenal mass
Indication Code: CARELON-ABDPEL-039
Anal Cancer
Indication Code: CARELON-ONC-008
Aneurysm of the abdominal aorta or iliac arteries
Indication Code: CARELON-VAS-029
Appendicitis
Indication Code: CARELON-ABDPEL-010
Biliary tract dilatation or obstruction
Indication Code: CARELON-ABDPEL-018
Bladder and Urothelial Cancers
Indication Code: CARELON-ONC-009
Bladder/Urothelial Cancers: Muscle Invasive
Indication Code: CARELON-ONC-011
Bladder/Urothelial Cancers: Non-muscle Invasive
Indication Code: CARELON-ONC-010
Bone Sarcoma
Indication Code: CARELON-ONC-042
Bowel obstruction
Indication Code: CARELON-ABDPEL-011
Brain and Spinal Cord Malignancy
Indication Code: CARELON-ONC-012
Breast Cancer
Indication Code: CARELON-ONC-013
Cancer screening, not otherwise specified
Indication Code: CARELON-ONC-007
Cancers of the Pleura, Thymus, Heart, and Mediastinum
Indication Code: CARELON-ONC-048
Cancers of Unknown Primary / Cancers Not Otherwise Specified
Indication Code: CARELON-ONC-014
Cervical Cancer
Indication Code: CARELON-ONC-015
Cholecystitis
Indication Code: CARELON-ABDPEL-019
Choledocholithiasis
Indication Code: CARELON-ABDPEL-020
Chronic lymphocytic leukemia or small lymphocytic lymphoma
Indication Code: CARELON-ONC-028
Colorectal Cancer
Indication Code: CARELON-ONC-016
Congenital and developmental conditions, not otherwise specified
Indication Code: CARELON-ABDPEL-001
Congenital or developmental vascular anomalies, not otherwise specified
Indication Code: CARELON-VAS-001
Constipation (Pediatric only)
Indication Code: CARELON-ABDPEL-012
Diffuse liver disease
Indication Code: CARELON-ABDPEL-021
Focal liver lesion
Indication Code: CARELON-ABDPEL-022
Gastric Cancer
Indication Code: CARELON-ONC-018
Gastrointestinal bleeding
Indication Code: CARELON-ABDPEL-015
Gastrointestinal stromal tumor (GIST)
Indication Code: CARELON-ONC-044
Head and Neck Cancer
Indication Code: CARELON-ONC-019
Hematuria (painless or undifferentiated)
Indication Code: CARELON-ABDPEL-041
Hepatocellular and Biliary Tract Cancers
Indication Code: CARELON-ONC-020
Hepatocellular carcinoma (HCC) screening
Indication Code: CARELON-ONC-006
Hepatomegaly
Indication Code: CARELON-ABDPEL-023
Hernia
Indication Code: CARELON-ABDPEL-052
Histiocytic Neoplasms
Indication Code: CARELON-ONC-021
Hydronephrosis
Indication Code: CARELON-ABDPEL-042
Infectious and inflammatory conditions including abscess– not otherwise specified
Indication Code: CARELON-ABDPEL-002
Inflammatory bowel disease (including Crohn’s disease and ulcerative colitis)
Indication Code: CARELON-ABDPEL-016
Jaundice
Indication Code: CARELON-ABDPEL-024
Kidney Cancer
Indication Code: CARELON-ONC-022
Lower extremity edema
Indication Code: CARELON-ABDPEL-060
Lung Cancer – Non-Small Cell
Indication Code: CARELON-ONC-023
Lung Cancer – Small Cell
Indication Code: CARELON-ONC-024
Lymphadenopathy
Indication Code: CARELON-ABDPEL-053
Melanoma
Indication Code: CARELON-ONC-030
Merkel Cell Carcinoma
Indication Code: CARELON-ONC-031
Multiple Myeloma
Indication Code: CARELON-ONC-032
Neuroendocrine Tumors
Indication Code: CARELON-ONC-033
Nonseminoma
Indication Code: CARELON-ONC-047
Ovarian Cancer – All Variants
Indication Code: CARELON-ONC-036
Pancreatic Cancer
Indication Code: CARELON-ONC-037
Pancreatic cancer screening
Indication Code: CARELON-ONC-005
Pancreatic duct dilatation
Indication Code: CARELON-ABDPEL-035
Pancreatic mass, indeterminate cystic (including suspected IPMN/IPMT)
Indication Code: CARELON-ABDPEL-037
Pancreatic mass, indeterminate solid
Indication Code: CARELON-ABDPEL-036
Pancreatitis
Indication Code: CARELON-ABDPEL-038
Paraneoplastic Syndrome
Indication Code: CARELON-ONC-038
Penile, Vaginal, and Vulvar Cancers
Indication Code: CARELON-ONC-039
Polycystic kidney disease
Indication Code: CARELON-ABDPEL-044
Poorly-differentiated neuroendocrine tumor
Indication Code: CARELON-ONC-035
Primary sclerosing cholangitis
Indication Code: CARELON-ABDPEL-025
Prostate Cancer
Indication Code: CARELON-ONC-040
Pyelonephritis
Indication Code: CARELON-ABDPEL-045
Renal artery stenosis/Renovascular hypertension
Indication Code: CARELON-ABDPEL-046
Renal masses (includes renal cysts)
Indication Code: CARELON-ABDPEL-047
Retroperitoneal conditions
Indication Code: CARELON-ABDPEL-055
Seminoma
Indication Code: CARELON-ONC-046
Soft Tissue Sarcoma
Indication Code: CARELON-ONC-043
Splenic mass
Indication Code: CARELON-ABDPEL-049
Splenomegaly
Indication Code: CARELON-ABDPEL-050
Suspected or Known Metastases
Indication Code: CARELON-ONC-051
Thyroid Cancer
Indication Code: CARELON-ONC-049
Transplant-related imaging
Indication Code: CARELON-ABDPEL-056
Trauma, not otherwise specified
Indication Code: CARELON-ABDPEL-003
Tumor or neoplasm – not otherwise specified
Indication Code: CARELON-ABDPEL-004
Uterine Cancer
Indication Code: CARELON-ONC-050
Vasculitis
Indication Code: CARELON-VAS-003
Well-differentiated neuroendocrine tumor
Indication Code: CARELON-ONC-034
Standard prior authorization requests are typically processed within 3–5 business days. Urgent/expedited requests may be processed within 24–72 hours when clinically necessary.
Most plans allow 30–60 days to file a first-level appeal. Expedited appeals for urgent cases are typically processed within 72 hours.
⚠ MRI uses no ionizing radiation, which is an important clinical consideration when choosing between MRI and CT.